Abstract

BAV has had resurgence in association with the dissemination of TAVR. The lack of clear mortality benefit from BAV does not translate to lack of efficacy as a palliative therapy. BAV remains a useful bridge to surgical AVR or TAVR, and for symptom relief in patients who are not candidates for either AVR approach. It is also useful as a diagnostic test for patients with low gradient-low output AS, and for those with mixed pulmonary and aortic valvular disease. BAV is used commonly for TAVR predilation, and this is sometimes helpful for annulus size assessment. Careful attention to balloon diameter selection and the details of technique are important for optimizing outcomes.

Copyright © 2015 Science International Corp.

Key Words
Balloon • Aortic • Valvuloplasty • General

Introduction

It is widely recognized that balloon aortic valvuloplasty balloon aortic valvuloplasty (BAV) does not contribute to an improvement in survival among nonsurgical or very high-risk patients with aortic stenosis. Unfortunately, the value of BAV as a palliative therapy has been overlooked in the shadow of this lack of mortality benefit. Clinical improvement after BAV occurs in the vast majority of patients. While in many this clinical improvement is short-lived, a majority of patients feel improved symptoms for as long as 1 year [1]. The utility of this therapy as a palliative treatment is seen best among patients, who truly have no other option [2]. For example, the extreme risk patient, who is a candidate for neither surgical nor transcatheter AVR may undergo BAV periodically for relief of symptoms. In our practice, there are patients, who have had roughly once yearly BAV procedures over a period of 2 or 3 years. This was, of course, more common before the availability of TAVR.

Indications for Balloon Aortic Valvuloplasty (BAV)

Contemporary indications for balloon aortic valvuloplasty (BAV) in adults are framed by the use of transcatheter aortic valve replacement (TAVR) as the mainstay of therapy for patients with aortic stenosis (AS) who are high risk for surgical valve replacement (SAVR) [3]. BAV has clinical utility in several circumstances in current practice. The 2014 AHA/ ACC guideline for the management of patients with valvular heart disease characterizes this in a single level llb (level of evidence C) recommendation, stating, “Percutaneous aortic balloon dilation may be considered...”
as a bridge to surgical AVR or TAVR in patients with severe symptomatic AS" [4,5]. This defines an important role for BAV among patients who are unstable or in refractory heart failure prior to valve replacement with either SAVR or TAVR [6]. These patients may present with refractory heart failure or shock, and BAV can make them more manageable for the short term.

BAV is also used in several other clinical situations (Table 1). Another important utility of BAV is as a diagnostic test. Patients with low gradient and low output aortic stenosis with low left ventricular ejection fraction represent a frequent diagnostic conundrum. Prior to aortic valve replacement, BAV in this population may unmask the myocardial reserver for a more invasive valve replacement therapy. The best example of this patient group is those with mixed chronic lung and valvular heart disease. The degree to which they may improve after valve therapy is often uncertain, and those who have a favorable response to BAV may be expected to similarly benefit from aortic valve replacement.

A more controversial use of BAV is prior to non-cardiac surgery. While many patients with severe aortic stenosis can undergo non-cardiac surgery when special care is taken to manage their hemodynamic situation, there are clearly patients, who have no reserve for whom management during non-cardiac surgery is challenging. The patient, who presents with an absolute aortic valve area less than 0.5 cm², or those with low cardiac output, very high pulmonary or pu-

Table 1. Indications for BAV

<table>
<thead>
<tr>
<th>Bridge to SAVR</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stabilize shock</td>
<td></td>
</tr>
<tr>
<td>Treat severe CHF</td>
<td></td>
</tr>
<tr>
<td>Bridge to TAVI</td>
<td></td>
</tr>
<tr>
<td>Symptom relief</td>
<td></td>
</tr>
<tr>
<td>Stabilization while evaluation is undertaken</td>
<td></td>
</tr>
<tr>
<td>Diagnostic test: see how patient responds</td>
<td></td>
</tr>
<tr>
<td>Low gradient/low output patient</td>
<td></td>
</tr>
<tr>
<td>Mixed lung and valve disease</td>
<td></td>
</tr>
<tr>
<td>Therapy for &quot;no-option&quot; patient</td>
<td></td>
</tr>
<tr>
<td>Anyone can undergo AVR</td>
<td></td>
</tr>
<tr>
<td>Apical-descending aorta conduit is an option for some</td>
<td></td>
</tr>
<tr>
<td>Pre-op for non-cardiac surgery</td>
<td></td>
</tr>
<tr>
<td>Predilatation</td>
<td></td>
</tr>
<tr>
<td>Sizing</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Hand injection of contrast during BAV with a 22mm balloon showed locking of the balloon and no contrast regurgitation around the balloon.

Figure 1 Video.
Pulmonary wedge pressures, or refractory symptomatic heart failure, may be stabilized enough by BAV to make non-cardiac surgery more tolerable for both the patient and the Anesthesia Team [7].

Recently, the major use of BAV has been for predilatation during TAVR procedures. While the need for predilatation can be argued for some patient groups and for many average TAVR procedures, another utility of BAV for TAVR is to help with valve annulus sizing or choice of prosthesis size [8]. When predilatation with a balloon matched to the expected annulus size yields a sealing of the annulus evidenced by contrast injection during the balloon inflation, greater confidence can be found for a TAVR valve with the frame corresponding to the balloon size. Conversely, when the balloon will not lock in the valve, and a contrast injection during balloon inflation results in clear contrast regurgitation into the left ventricle, the balloon presents an undersized diameter for a given valve annulus.

Special care must be taken to be sure that the fully inflated predilatation balloon size measurement is accurate. Many balloons are manufactured with some variability in the technical specification. In addition, hand inflation using a large syringe typically results in under-filling of the balloon, and it is likely in that setting that the balloon will not achieve its nominal diameter. Two methods to insure correct and full inflation include either use of a volume driven inflation with an inflation device, or the addition of a side syringe and a high pressure stopcock to the larger hand inflation syringe.

BAV can be used as an aid to sizing for TAVR [9]. It is not uncommon to have ambiguity for the selection of TAVR device size, even with CT annulus measurements. This problem results when patients are truly on the borderline between valve prosthesis sizes based simply on measurements, and is exacerbated by the challenges of heavily calcified leaflets or left ventricular outflow tract, and the underappreciated problem of suboptimal CT scan images for analysis. One method favored by some operators to help resolve
ambiguity when TAVR device sizing is problematic is to inject contrast in the aortic root during the BAV for TAVR predilatation. A balloon size is typically selected to approximate the short axis CT diameter of the valve. The short axis dimension of the annulus can also be ascertained from the typical transthoracic or transesophageal log axis echo.

The balloon is inflated and contrast is injected into the aortic root at the peak of balloon inflation (Figure 1). CT measurements prior to planned TAVR were borderline for a 23-mm vs. a 26-mm Edwards S3 implant. Hand injection of contrast during BAV with a 22-mm balloon showed locking of the balloon and no contrast regurgitation around the balloon. A 23-mm valve was implanted with a good result, including minimal paravalvular leak. The use of hand injections or various forms of power injections is completely non-standardized. A caveat is that the tip of the pigtail used for injection may be trapped between the balloon and the aortic wall, especially if the sinotubular junction is small in diameter, and a power injection may result in a dissection of the aortic root. During contrast injections it is often difficult to assess whether there is significant contrast regurgitation around the balloon. Generally little or no contrast regurgitation into the left ventricle especially when associated with a balloon that locks into the native aortic anulus during inflation suggests that a valve prosthesis frame of about that diameter will be successful.

BAV Techniques

Retrograde BAV

The technique retrograde BAV was described initially for pediatric patients in 1985 and first reported in adult patients with degenerative calcific aortic stenosis in 1986. The technique was largely unchanged for two decades. More recently, several advances have contributed to the predictability of the procedure and its practically [10]. Balloons for BAV
Figure 4. Rapid right ventricular pacing to cause hypotension, at a heart rate between 170 and 200 beats per minute, is initiated and when the blood pressure falls, the valvuloplasty balloon is inflated.

Figure 5. A 7-French single-lumen balloon catheter is inflated in the left atrium and with counterclockwise rotation of a standard Mullins sheath the balloon tip catheter is floated across the mitral valve.
advent of rapid right ventricular pacing during balloon inflations to minimize balloon movement or "watermelon seeding" has made the procedure much more successful. Particularly, the
more manageable. The basic technique involves obtaining femoral arterial access, performing suture preclosure, and placing an arterial sheath ranging in diameter from 10 up to 14 French, depending on the balloon type and size. Meticulous technique using fluoro- or ultrasound-guided femoral access to ensure sheath insertion in a non-calcified segment of the common femoral artery is critical (Figure 2). After access is obtained, the valve is crossed using standard techniques (Figure 3) and stiff exchange wire is placed as a rail for delivery of the balloon. The balloon is advanced retrograde over the guidewire into the left ventricle and positioned across the native aortic valve annulus. Rapid pacing at a heart rate, typically between 170 and 200 beats per minute is initiated and when the blood pressure falls, the balloon is inflated (Figure 4). After full inflation is achieved, the balloon is withdrawn and rapid pacing discontinued. If the balloon was ejected from the ventricle during the inflation, and blood pressure recovery has been adequate, a second inflation may be performed. At that point, the result is assessed and if appropriate to the situation, a larger balloon can be used when the result does not meet the planned expectations. The balloon and wire are withdrawn, and the existing suture is used to close the arterial sheath insertion site, usually with a wire left in place so that if the preclosure fail, an additional Perclose device can be used or a sheath inserted so that manual compression may be undertaken when the anticoagulation normalizes or is reversed. Careful attention to the hemodynamics before and after each inflation is crucial. While it is not necessary to re-measure the transaortic gradient after each inflation it is critical to carefully assess the changes in aortic diastolic pressure as an indicator of increase aortic insufficiency. If a second inflation is necessary, the possibility of more than mild aortic insufficiency should be excluded before proceeding for the second attempt.

**Antegrade BAV**

A much less utilized approach is to deliver a balloon into the native aortic annulus using transvenous-trans-septal access [11]. From the trans-septal puncture into the left atrium, a single-lumen balloon catheter can be floated into the left ventricle and then into the aorta. This allows delivery of a stiff wire antegrade so that the balloon for BAV may be
introduced on the venous side of the circulation and tracked through the left atrium and left ventricle to straddle the aortic valve. Antegrade BAV is technically more demanding than retrograde BAV. Many of the procedure steps are unfamiliar to many BAV and TAVR operators. One of the advantages of antegrade BAV is utilization of a vein rather than an artery for access. This is occasionally useful in patients with severe peripheral arterial disease. Another advantage is stability of the balloon during inflation in the aortic valve even without rapid pacing. Since there is an arterial-venous loop, the balloon can be controlled from both antegrade and retrograde directions and is highly stable. In addition, the use of venous access allows for the utilization of much larger diameter balloons. In our series, this resulted in larger acute valve areas BAV compared to a retrograde technique.

The next several paragraphs will detail the specific procedure steps of antegrade BAV. The initial set up for antegrade BAV includes 7 French left femoral arterial and 7 or 8 French left femoral venous access, and for the trans-septal puncture, 14 French right femoral venous access. The arterial access sheath size is required to place a 10mm gooseneck snare via the left femoral arterial sheath and still have enough room for arterial pressure measurement. The left femoral venous access is for initially pulmonary artery catheterization and cardiac output measurement, and subsequently for medication administration if needed. The 14 French right femoral venous access facilitates trans-septal puncture and allows for placement of a Inoue balloon catheter.

After access is obtained, trans-septal puncture is performed. A posterior mid fossa level puncture allows easiest access to the mitral orifice. A 7 French single-lumen balloon catheter is inflated in the left atrium and with counterclockwise rotation of a standard Mullins sheath the balloon tip catheter is floated across the mitral valve (Figure 5). At this point, the transaortic valve pressure gradient can be measured. A standard 0.035” J-tip wire can be introduced into the single-lumen balloon catheter with a large curve added, so that the balloon catheter can be directed around the left ventricular apex (Figure 6). At this point, it is sometimes necessary to switch to a floppy tip straight wire such as a Whooley wire to cross the aortic valve antegrade and with the single-lumen catheter balloon deflated, pass the balloon catheter.
The stretched balloon is introduced into the left atrium, and then unstretched. The balloon is tracked around the arteriovenous loop through the mitral valve and into the aortic valve. It sometimes requires pushing from the venous side and pulling on the arterial side to get the balloon into position in the native aortic valve. Without any need for rapid pacing, the balloon is inflated in its usual stepwise fashion (Figure 11). The distal part of the balloon was inflated on the arch side of the aortic valve and pulled back to engage the valve and then the balloon is fully inflated. A rapid inflate-deflate is important. It is also important, as soon as the balloon deflated, to back it out of the aortic valve into the left atrium, and to re-establish the arteriovenous loop so that there is no tension on the mitral valve leaflets.

In some cases, progressive hypotension begins as soon as the arteriovenous loop is introduced and the procedure must be aborted. In other cases, the onset of this mitral regurgitation related hypotension is gradual and if the procedure can be accomplished rapidly, the arteriovenous loop can be decompressed or removed before significant hypotension occurs.
Unlike the case in retrograde BAV, the Inoue balloon completely occludes the aortic outflow and this is often poorly tolerated by the left ventricle. Episodes of slow pressure recovery with the antegrade technique are more common than with the retrograde technique. It is my practice to have both atropine and epinephrine or phenylephrine open and available for this possibility. Epinephrine or phenylephrine doses of 50 up to 250 µg are usually sufficient without causing rebound hypertension.

After the balloon catheter has been pulled back into the left atrium it can be stretched and removed over the wire. At this point, it is critical to place a diagnostic catheter from the venous side over the 0.032-inch wire and pass this catheter across the mitral and aortic valves and into the aorta. The gooseneck snare can be removed, and then the exchange wire pulled back into the diagnostic catheter. A pigtail is best used for this purpose, as the pigtail is pulled back it can be left in the left ventricle. This is easier if the Mullins sheath is introduced over the wire before the pigtail is placed. A post intervention gradient can be assessed to determine the results of the procedure. Covering the arteriovenous loop wire with a diagnostic catheter before removing the wire is critical, since the wire can "cheese cut" the mitral valve if it is pulled back without protecting the valve.

**Future Perspectives in Aortic Valvuloplasty Technologies**

Most of the current balloons in use for aortic valvuloplasty were not specifically designed for this purpose and thus have limitations. They have predominantly been peripheral angioplasty balloons which are cylindrical in shape, with a spectrum of balloon diameter lengths and compliance characteristics. Until recently, none of these have been FDA approved for the BAV indication. The re-emergence of “stand-alone” BAV, TAVR pre- and post-dilations have led to balloon innovations. One such balloon is the True Dilation Balloon Valvuloplasty Catheter (C. R. Bard, Inc., Tempe, Arizona, USA). This balloon is cylindrical in shape. The balloon matrix is embedded with high-strength fibers rendering the balloon noncompliant and thus achieving precise diameters when inflated. In addition, the shaft size is approximately 10 Fr to permit larger inflation lumens and thus faster inflation and deflation times. Rapid right ventricular pacing is still
ther testing with the intention of coming to market has been frozen.

A second novel aortic valvuloplasty balloon, the V8 (Intervalve, Inc., Plymouth, Minnesota, USA) has a geometric (i.e., “hourglass”) configuration designed to take advantage of the complex aortic valve and adjacent anatomy (Figure 12). Intended benefits include: 1) precise balloon position with stable fixation with or without rapid pacing, 2) greater resultant aortic valve areas due to hyperextension of the valve leaflets into the sinuses of Valsalva by the proximal bulb, and 3) enhanced safety with the retention of a narrower balloon waist, reducing the likelihood of annular rupture. In a propensity-matched study with 40 patients, the delta increase in AVA by echocardiography for the V8 balloon was 0.30 ± 0.23 cm² vs. 0.17 ± 0.21 cm² for standard cylindrical balloons (P = 0.063). There was no severe AI, new IVCD’s, or need for PPMs. There were no major adverse events in the V8 group defined as procedure-related death, stroke or emergency surgery [12]. As per direct communication with Intervalve, in over 400 cases procedural mortality was less than 0.5%. The V8 has a 10Fr shaft and permits rapid inflation/deflation times. A subsequent iteration in development has a radio-opaque ring on the balloon waist to assist in establishing co-planarity with the target AV annulus for TAVR positioning.

A third novel valvuloplasty balloon, the Valvuloplast Balloon (Angioscore, Fremont, California, USA) is cylindrical in shape and has a helical wire lattice on the exterior balloon surface to enhance fixation and potentially augment AVA by proposed leaflet scoring. This balloon is in early phase testing and not yet FDA approved. It has been related to the authors by direct communication with Angioscore that further testing with the intention of coming to market has been frozen.

Finally, catheter-based concepts for calcific valve leaflet remodeling have been proposed. Energy sources for consideration include high-frequency ultrasound, with application of the lithotripsy, and transmission of vibration through direct catheter-to-leaflet contact with a mechanical device.

Pre-shaped, extra stiff, guide wires including the “Safari” wire (left-Boston Scientific, Plymouth, MN) and “Confida” (right-Medtronic, Minneapolis, MN) have recently been brought to market for TAVR as well as BAV.

Figure 12. The Intervalve V8 balloon has a geometric “hourglass” configuration designed to take advantage of the complex aortic valve and adjacent anatomy.

Figure 13. Pre-shaped, extra stiff, guide wires including the “Safari” wire (left-Boston Scientific, Plymouth, MN) and “Confida” (right-Medtronic, Minneapolis, MN) have recently been brought to market for TAVR as well as BAV.
Conclusions

BAV has had resurgence in association with the dissemination of TAVR. The lack of clear mortality benefit from BAV does not translate to lack of efficacy as a palliative therapy. BAV remains useful a bridge to surgical AVR or TAVR, and for symptom relief in patients who not candidates for either AVR approach. It is also useful as a diagnostic test for patients with low gradient-low output AS, and for those with mixed pulmonary and aortic valvular disease. BAV is used commonly for TAVR predilatation, and this is sometimes helpful for annulus size assessment. Careful attention to balloon diameter selection and the details of technique are important for optimizing outcomes.

Conflict of Interest

Dr Feldman is a consultant to Abbott, BSC, and Edwards. Dr Pedersen has ownership interest in InterValve.

Comment on this Article or Ask a Question

References


Cite this article as: Feldman T, Sarraf M, Pedersen W. Balloon Aortic Valvuloplasty: Patient selection and technical considerations. Structural Heart Disease 2015;1(1): 20-32. DOI: http://dx.doi.org/10.12945/j.jshd.2015.00009-14